Up next

Autoplay

#489 Overactive Bladder Medication Yearly Prescribing and Expenditure Trends

1 Views • 08/24/25
Share
Side Effects
Side Effects
Subscribers
0

Overactive Bladder Medication Yearly Prescribing and Expenditure Trends

Chua K1, Patel H1, Tabakin A1, Doppalapudi S1, Hyams E2, Tunuguntla H1

1. Rutgers Robert Wood Johnson Medical School, 2. Columbia University Medical Center

KEYWORDS: Detrusor Overactivity, Incontinence, Overactive Bladder

Anticholinergics have a high discontinuation rate and many associated unfavorable adverse effects such as dry mouth, constipation and cognitive changes. [1] Mirabegron was approved by the FDA in 2012 as the first beta-3 agonist to treat overactive bladder and has been shown to have an increased persistence of use with less anticholinergic side effects. [2] This study aims to examine how prescribing patterns have changed since the approval of mirabegron.

Read the full abstract text here: https://www.ics.org/2020/abstract/489

Show more
0 Comments sort Sort By

Up next

Autoplay